

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma

Information for the public

Published: 10 April 2024

www.nice.org.uk

Cabozantinib (Cabometyx) with nivolumab (Opdivo) is available on the NHS. It is a possible treatment for untreated advanced renal cell carcinoma in adults if:

- they have an intermediate or poor prognosis
- the alternative treatment would be nivolumab with ipilimumab or lenvatinib with pembrolizumab.

If you are not eligible for cabozantinib with nivolumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on kidney cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Kidney Cancer UK](#), 01223 870008
- [Action Kidney Cancer](#), 0800 121 8721
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5862-7